BPC-157 (Pentadecapeptide)
Is BPC-157 Legal?
BPC-157 is not a controlled substance in the UK or the US, so possession is not an offence in the way it would be for a scheduled drug. It also holds no marketing authorisation anywhere, so it cannot lawfully be supplied or advertised for human use. It is unapproved rather than illegal, and those are different things.
Key facts
- UK controlled drug status
- Not scheduled
- UK marketing authorisation
- None
- US scheduling
- Not scheduled
- US compounding
- FDA Category 2, 2023
- Sport
- Prohibited under WADA S0
Unapproved and illegal are not the same category
Controlled drug legislation schedules substances by abuse potential. BPC-157 appears in no schedule in either the UK or the US. Medicines legislation is separate and governs what may be supplied as a medicine; BPC-157 holds no authorisation under it anywhere in the world. The first means possession is not an offence. The second means supply for human use is.
Is BPC-157 legal in the UK
It is not a controlled drug under the Misuse of Drugs Act, and there is no UK marketing authorisation for any product containing it. Supplying or advertising it for human use would therefore breach the Human Medicines Regulations 2012, irrespective of its scheduling. Supply for laboratory research, on the basis that it is not for human or veterinary use, sits outside that regime.
Research material referenced
BPC-157 5mg — third-party HPLC tested
The FDA compounding decision
In 2023 the FDA placed BPC-157 in Category 2 of its 503A bulk drug substances review — substances with significant safety risks identified for compounding use. That is not a scheduling action and it does not make possession unlawful, but it is the clearest formal regulatory statement any agency has made about the compound, and it went against it.
Sport is a separate regime
WADA's prohibited list includes category S0, non-approved substances, which captures compounds with no current approval for human therapeutic use. BPC-157 falls within it. An athlete subject to testing should treat this as independent of whether possession is lawful, because it is.
Extended research context
The BPC-157 (Pentadecapeptide) deep dive
Deep dive: the pentadecapeptide sequence
BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound' — the group's original characterisation term.
Two forms: acetate salt vs arginate
BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).
Reading a BPC-157 CoA
A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.
Research applications
- ▸Cell-culture models of gut epithelial integrity
- ▸Tendon fibroblast migration and collagen-synthesis assays
- ▸Angiogenesis models involving VEGF and NO signalling
- ▸Stability studies comparing acetate vs arginate salt forms
- ▸Analytical reference for pentadecapeptide HPLC methods
Handling checklist
- ✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
- ✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
- ✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
- ✓Protect from light and repeated warming
- ✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Mixing acetate and arginate BPC-157 across a study
Fix: Choose one salt form and stay with it — different masses and solubility.
✗ Assuming stability at room temperature
Fix: Refrigerate reconstituted solution; discard after 28 days.
✗ Buying without a CoA
Fix: Only source from suppliers that publish batch HPLC + mass-spec data.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- What does BPC-157 stand for?
- Is BPC-157 the same as pentadecapeptide?
- Who discovered BPC-157?
- What is the difference between BPC-157 acetate and arginate?
- How is BPC-157 reconstituted for research?
Frequently asked questions
- Is BPC-157 legal in the UK?
- It is not a controlled substance under the Misuse of Drugs Act. It also holds no UK marketing authorisation, so supplying or advertising it for human use breaches the Human Medicines Regulations 2012.
- Is BPC-157 banned by the FDA?
- It is not scheduled, but in 2023 the FDA placed it in Category 2 of its 503A bulk substances review — substances with significant safety risks identified for compounding. That is the clearest formal regulatory position taken on it.
- Is BPC-157 allowed in sport?
- No. WADA's category S0 covers non-approved substances with no current human therapeutic approval, and BPC-157 falls within it. This is independent of whether possession is lawful.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSikiric P et al. — Pharmaceuticals (Basel) 2023 (PMID 37513963)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels — Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy — Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157 — J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat — J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 71300630)pubchem.ncbi.nlm.nih.gov
- PubMedNIH PubMed — Complete BPC-157 literature (Sikiric group)pubmed.ncbi.nlm.nih.gov
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More BPC-157 (Pentadecapeptide) articles
- Why BPC-157 and TB-500 Are Called the Wolverine StackAn informal name for combining two repair-studied peptides, after the comic character who heals fast. What the name promises and what the literature supports.
- Is Oral BPC-157 Absorbed? What the Rat Data ShowsUnlike most peptides, BPC-157 was given orally in the original rodent work and still produced effects. What that does and does not establish for a capsule.
- What Is BPC-157? Origin, Sequence and EvidenceBPC-157 is a 15-residue peptide derived from a gastric juice protein. Structure, mechanism, and the registered clinical trials most coverage omits.
- BPC-157 in the Published LiteratureDecades of Zagreb-group preclinical work, earlier clinical development as PL-14736, and a Phase 2 trial recruiting now. How the evidence actually stacks up.
- The Zagreb Research ProgrammePredrag Sikirić and colleagues at the University of Zagreb have produced most of the BPC-157 literature over three decades. What that concentration means.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchRetatrutide Molecular Structure and Properties
- GHK-Cu (Copper Peptide)Research GHK-Cu and Cosmetic Copper Peptides Compared
- TB-500 (Thymosin β4 fragment)TB-500 in the Published Research
- CJC-1295 & IpamorelinWhy These Two Are Studied Together
- Peptide ReferenceLyophilisation: Why Peptides Arrive as Powder
- Bacteriostatic WaterHow Benzyl Alcohol Works as a Preservative
- Research & Regulatory NewsReading a Programme From Its Trial Registrations
- GLP-1 & Incretin ScienceWhy a Drug Works Less Well Than Its Trial Said
- MOTS-c (Mitochondrial Peptide)MOTS-c Mechanism: AMPK Activation via the Folate Cycle
- Semax (ACTH Fragment Peptide)What Are Glyprolines? The Pro-Gly-Pro Motif Explained
- Selank (Tuftsin Analogue)Selank and GABAergic Signalling
- DSIP (Delta Sleep-Inducing Peptide)What the Antibody Found in Peripheral Tissue
- KLOW (Blend)Half of This Blend Is Small Enough to Share a Route
- GLOW (Blend)The Two Repair-Literature Components
- MT-2 (Melanotan II)The Receptor a Non-Selective Agonist Also Reaches
- IGF-1 LR3A Strong Rationale That Did Not Translate
- GlutathioneA Routine Liver Test That Measures a Glutathione Enzyme
- NAD+Two Products in This Catalogue, One Connected System
- KPVDelete the Transporter and the Effect Disappears